Read by QxMD icon Read

hcv clearance

G Kamkamidze, M Butsashvili, K Gendzekhadze
Hepatitis C virus (HCV) infection remains one of the most important blood-borne diseases worldwide with about 130-170 million people chronically infected with hepatitis C virus, and more than 350 000 people die from hepatitis C-related liver diseases each year. Infection with HCV becomes chronic in approximately 80% of cases, while in up to 20% of cases hepatitis C virus is cleared from the human organism. Chronic infections of hepatitis C often leads to the end-stage liver diseases such as cirrhosis and hepatocellular carcinoma...
September 2016: Georgian Medical News
Ming-Lung Yu, Chung-Feng Huang, Ming-Lun Yeh, Pei-Chien Tsai, Ching-I Huang, Meng-Hsuan Hsieh, Ming-Yen Hsieh, Zu-Yau Lin, Shinn-Cherng Chen, Jee-Fu Huang, Chia-Yen Dai, Wan-Long Chuang
Purpose Age and hepatic fibrosis are the factors that increase the risk of hepatocellular carcinoma (HCC) over time. We aimed to explore their impact at the initiation of antiviral therapy on HCC among chronic hepatitis C (CHC) patients. Experimental Design A total of 1281 biopsy-proven CHC patients receiving interferon-based therapy were followed for a mean period of 5.5 years. Results The 5-year cumulative incidence of HCC did not differ between non-SVR and SVR patients who were <40 years old (7.7 % vs...
October 12, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Akira Sato, Toshiya Ishii, Kayo Adachi, Hideaki Takahashi, Fumiaki Sano, Nobuyuki Matsumoto
Following interferon-based therapy for chronic hepatitis C, the negativity of hepatitis C virus RNA is essential to achieve viral clearance at the end of treatment. We report a case of clearance of chronic hepatitis C virus infection following early discontinuation (at 6 weeks) of peginterferon plus ribavirin therapy, without negativity for hepatitis C virus RNA during the treatment period. The patient was a 76-year-old Japanese male infected with hepatitis C virus genotype 1b and TT of IL28B rs8099917. Hepatitis C virus RNA remained positive at persistently low levels for more than 2 months after the cessation of therapy and became negative at 7 months after the discontinuation of therapy...
May 2016: Case Reports in Gastroenterology
N Suzuki, A Hirakawa, M Kishimoto, T Kanematsu, M Ogawa, H Kiyoi, T Matsushita
BACKGROUND: Continuous infusion (CI) of recombinant FVIII (rFVIII) concentrates has been reported as an effective and safe method to achieve haemostasis during major surgeries or severe bleeding events. For more effective and safer CI, better understanding of in vivo recovery (IVR) and clearance (CL) issues is imperative. OBJECTIVE: We investigated the following factors affecting IVR and CL using univariate and multivariate regression analyses during 47 CIs in 34 patients: rFVIII concentrate type, haemophilia severity, blood type, the presence of hepatitis C virus (HCV) or human immunodeficiency virus (HIV), age and body mass index (BMI)...
October 5, 2016: Haemophilia: the Official Journal of the World Federation of Hemophilia
J Hengst, C S Falk, V Schlaphoff, K Deterding, M P Manns, M Cornberg, H Wedemeyer
BACKGROUND:  Persistent infection with the hepatitis C virus (HCV) causes profound alterations of the cytokine and chemokine milieu in peripheral blood. However, it is unknown to what extend these alterations affect the progression of liver disease and whether HCV clearance normalizes soluble inflammatory mediators. METHODS:  We performed multianalyte profiling of 50 plasma proteins of 28 patients with persistent HCV infection and advanced stages of liver fibrosis or cirrhosis and 20 controls with fatty liver disease...
September 28, 2016: Journal of Infectious Diseases
Sven Mensing, Doerthe Eckert, Shringi Sharma, Akshanth R Polepally, Amit Khatri, Thomas J Podsadecki, Walid M Awni, Rajeev M Menon, Sandeep Dutta
AIM: To characterize the population pharmacokinetics of a triple direct-acting antiviral (DAA) regimen (3D) (ombitasvir, paritaprevir-ritonavir, and dasabuvir) and adjunctive ribavirin and estimate covariate effects in a broad spectrum of subjects with hepatitis C virus (HCV) genotype 1 infection. METHODS: Pharmacokinetic data from six phase 3 studies and one phase 2 study in subjects receiving the currently approved doses of the 3D ± ribavirin regimen for treating HCV genotype 1 infection for 12 or 24 weeks were characterized using separate population pharmacokinetic models built using each component of the regimen from non-linear mixed-effects methodology in NONMEM 7...
September 23, 2016: British Journal of Clinical Pharmacology
Patrick Ingiliz, Thomas C Martin, Alison Rodger, Hans-Jürgen Stellbrink, Stefan Mauss, Christoph Boesecke, Mattias Mandorfer, Julie Bottero, Axel Baumgarten, Sanjay Bhagani, Karine Lacombe, Mark Nelson, Jürgen K Rockstroh
BACKGROUND AND AIMS: Moderate cure rates of acute hepatitis C virus (HCV) infections with pegylated interferon and ribavirin (PR) have been described in the last decade in men who have sex with men (MSM) who are coinfected with the human immunodeficiency virus (HIV). However, a subsequent high incidence of HCV reinfections has been reported regionally in men who both clear the infection spontaneously or who respond to treatment. METHODS: Retrospective analysis of reinfections in HIV infected MSM in eight centers from Austria, France, Germany, and the UK within the NEAT network between May 2002 and June 2014...
September 17, 2016: Journal of Hepatology
Markus H Heim, Pierre-Yves Bochud, Jacob George
Hepatitis C virus (HCV) is a major cause of chronic viral hepatitis that can lead to cirrhosis and hepatocellular carcinoma. Only a minority of patients can clear the virus spontaneously. Elimination of HCV during acute infection correlates with a rapid induction of innate, especially interferon (IFN)-induced genes, and a delayed induction of adaptive immune responses. There is a strong association between genetic variants in the IFNλ (IL28B) locus with the rate of spontaneous clearance. Individuals with the ancestral IFNλ4 allele capable of producing a fully active IFNλ4 are paradoxically not able to clear HCV in the acute phase and develop chronic hepatitis C (CHC) with more than 90% probability...
October 2016: Journal of Hepatology
M El-Bendary, M Neamatallah, G Esmat, E Kamel, H Elalfy, T Besheer, D Eldeib, A-H Eladl, M El-Setouhy, A-H El-Gilany, A El-Waseef
Hepatitis C infection is a global pandemic. HLA-DQB1 alleles are believed to have an effective role in immune response against HCV including susceptibility to or protection from this infection. The aim of this study was to investigate the contribution of HLA-DQB1 alleles in the outcome of HCV genotype-4 infection through a family-based association study. Egyptian families with HCV (324) were recruited for this study (324 index positive for RNA-HCV, 225 positive relatives representing chronic hepatitis C cases and 582 family members negative for HCV-RNA [control], 63 of whom spontaneously cleared the virus...
September 7, 2016: Journal of Viral Hepatitis
Daniel J Smith, Ashly E Jordan, Mayu Frank, Holly Hagan
BACKGROUND: Hepatitis C virus (HCV) infection causes significant morbidity and mortality among people who inject drugs (PWID) and HIV+ men who have sex with men (MSM). Characterizing spontaneous viral clearance of HCV infection among PWID and HIV+ MSM is important for assessing the burden of disease and treatment strategies in these populations. METHODS: Electronic and other searches of medical literature were conducted. Reports were eligible if they presented original data from upper-middle- and high-income countries on laboratory-confirmed HCV infection and spontaneous viral clearance among PWID or HIV+ MSM...
2016: BMC Infectious Diseases
Luz M Medrano, Norma Rallón, Juan Berenguer, María A Jiménez-Sousa, Vicente Soriano, Teresa Aldámiz-Echevarria, Amanda Fernández-Rodríguez, Marcial García, Francisco Tejerina, Isidoro Martínez, José M Benito, Salvador Resino
BACKGROUND AND AIMS: TRIM5 and TRIM22 are restriction factors involved in innate immune response and exhibit anti-viral activity. Single nucleotide polymorphisms (SNPs) at TRIM5 and TRIM22 genes have shown to influence several viral infections such as human immunodeficiency virus (HIV), hepatitis B, as well as measles and rubella vaccination. The aim of this study is to analyze whether TRIM5 and TRIM22 polymorphisms are associated with liver fibrosis inflammation-related biomarkers and response to pegylated-interferon-alpha plus ribavirin (pegIFNα/RBV) therapy in HIV/hepatitis C virus (HCV) coinfected patients...
2016: Journal of Translational Medicine
Akshanth R Polepally, Prajakta S Badri, Apurvasena Parikh, Lino Rodrigues, Barbara A Da Silva-Tillmann, Sven Mensing, Thomas J Podsadecki, Walid M Awni, Sandeep Dutta, Rajeev M Menon
BACKGROUND: The 3 direct-acting antiviral regimen (3D regimen) of ombitasvir, paritaprevir/ritonavir, and dasabuvir, with and without ribavirin, was evaluated in 1 Phase 2 trial and 6 Phase 3 trials in over 2,300 hepatitis C virus genotype 1-infected patients. Patients continued taking their protocol-permitted comedications while receiving the 3D ± ribavirin regimen. The effects of the comedications on exposures of the 3D regimen and ribavirin were examined. METHODS: Population pharmacokinetic model-predicted steady-state area under the curve (AUC24,ss) values were evaluated in the presence/absence of the comedications...
September 1, 2016: Antiviral Therapy
Sara Kishta, Reem Ei-Shenawy, Sobhy Kishta
Recent improvements have been made in the treatment of hepatitis C virus (HCV) infection with the introduction of direct-acting antiviral agents (DAAs). However, despite successful viral clearance, many patients continue to have HCV-related disease progression. Therefore, new treatments must be developed to achieve viral clearance and prevent the risk of HCV-related diseases. In particular, the use of pitavastatin together with DAAs may improve the antiviral efficacy as well as decrease the progression of liver fibrosis and the incidence of HCV-related hepatocellular carcinoma...
2016: F1000Research
Josep M Llovet, Augusto Villanueva
No abstract text is available yet for this article.
October 2016: Nature Reviews. Gastroenterology & Hepatology
Zobair M Younossi, Maria Stepanova, Linda Henry
BACKGROUND: The hepatitis C virus (HCV) infection has tremendous clinical, health-related quality-of-life (HRQOL), and economic burden on patients and the society. To assess the comprehensive impact of HCV infection, systematic tracking of HRQOL in patients with HCV infection is important. OBJECTIVE: The aim of this study was to systematically validate an HCV-specific HRQOL instrument, the Chronic Liver Disease Questionnaire-Hepatitis C Version (CLDQ-HCV), in patients with chronic HCV infection...
July 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
Camila Fernanda da Silveira Alves, Camila Schultz Grott, Vagner Ricardo Lunge, Jorge Umberto Béria, Daniela Cardoso Tietzmann, Airton Tetelbom Stein, Daniel Simon
Approximately one-third of the individuals infected with human immunodeficiency virus type 1 (HIV-1) are co-infected with hepatitis C virus (HCV). Co-infected patients have an increased risk for developing end-stage liver diseases. Variants upstream of the IFNL3 gene have been associated with spontaneous and treatment-induced clearance of HCV infection. Recently, a novel polymorphism was discovered, denoted IFNL4 ΔG > TT (rs368234815), which seems to be a better predictor of spontaneous clearance than the IFNL4 rs12979860 polymorphism...
July 2016: Genetics and Molecular Biology
Anna Rosa Garbuglia, Ubaldo Visco-Comandini, Raffaella Lionetti, Daniele Lapa, Filippo Castiglione, Gianpiero D'Offizi, Chiara Taibi, Marzia Montalbano, Maria Rosaria Capobianchi, Paola Paci
OBJECTIVES: Identifying the predictive factors of Sustained Virological Response (SVR) represents an important challenge in new interferon-based DAA therapies. Here, we analyzed the kinetics of antiviral response associated with a triple drug regimen, and the association between negative residual viral load at different time points during treatment. METHODS: Twenty-three HCV genotype 1 (GT 1a n = 11; GT1b n = 12) infected patients were included in the study. Linear Discriminant Analysis (LDA) was used to establish possible association between HCV RNA values at days 1 and 4 from start of therapy and SVR...
2016: PloS One
E Keoshkerian, M Hunter, B Cameron, N Nguyen, P Sugden, R Bull, A Zekry, L Maher, N Seddiki, J Zaunders, A Kelleher, A R Lloyd
Clearance of primary hepatitis C virus (HCV) infection has been associated with strong and broadly targeted cellular immune responses. This study aimed to characterize HCV-specific CD4+ effector and regulatory T-cell numbers and cytokine production during primary infection. Antigen-specific CD4+ T-cell responses were investigated in a longitudinal cohort of subjects from pre-infection to postoutcome, including subjects who cleared [n=12] or became chronically infected [n=17]. A cross-sectional cohort with previously cleared, or chronic infection [n=15 for each], was also studied...
August 25, 2016: Journal of Viral Hepatitis
José Velosa
Approximately one-third of patients infected with chronic hepatitis C virus (HCV) have cirrhosis, and this is likely to increase in the near future. The risk of complications, mainly the development of hepatocellular carcinoma, depends on the presence of cirrhosis, and a significant increase in the incidence of cirrhosis-related events, including mortality, is likely in the following years. All-oral therapy with direct-acting antivirals (DAAs) offers a safe and short treatment, with cure rates over 90% in compensated cirrhosis...
August 24, 2016: Antiviral Therapy
Minesh Mehta, Helal F Hetta, Enass A Abdel-Hameed, Susan D Rouster, MdMonir Hossain, Mohamed A Mekky, Nasr K Khalil, Wegdan A Mohamed, Mohamed A El-Feky, Shabaan H Ahmed, Enas A Daef, Mohamed A El-Mokhtar, Sayed F Abdelwahab, Ahmed Medhat, Kenneth E Sherman, Mohamed Tarek M Shata
The IL28B gene is associated with spontaneous or treatment-induced HCV viral clearance. However, the mechanism by which the IL28B single nucleotide polymorphism (SNP) affects the extra-hepatic HCV immune responses and its relationship to HCV pathogenesis have not been thoroughly investigated. To examine the mechanism by which IL28B affects HCV clearance. Forty Egyptian patients with chronic HCV infection receiving an Interferon/ribavirin treatment regimen were enrolled into this study. There were two groups: non-responders (NR; n = 20) and sustained virologic responders (SVR; n = 20)...
November 2016: Archives of Virology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"